Articles of Interest

Governor profits from Hep C drug tied to state prisons, opioid crisis

Profit Off The People –

July 22, 2018 – Scott’s Gilead investment appears to have begun in 2013, when the company’s stock began soaring after the groundbreaking Solvadi drug treatment was launched at a price of $1,000-a-pill, or $84,000 for a 12-week course. Harvoni and Epclusa are other expensive Hep C drugs the company makes and commonly used. But increasing competition from other products has caused Gilead’s stock to stall after years of sharp growth. In those early go-go years, both public and private payers derided the Hep C drugs as budget busters. A U.S. Senate Finance Committee investigation in 2015 concluded that Gilead put profits before patients in pricing its Hep C drugs, refusing to lower prices or offer discounts to maximize returns and stave-off competitors. The same probe found that Medicaid programs across the nation were able to treat less than 3 percent of the 700,000 patients infected with the disease, despite spending more than $1 billion on Solvadi.

Full Story @ News-JournalOnline.com

Leonard Buschel

Share
Published by
Leonard Buschel

Recent Posts

Archaeologists Uncover Previously Unknown Effect of Tobacco

ALWAYS WITH YOU – Nov. 2, 2024 - Archaeologists have uncovered a previously unknown effect…

5 hours ago

In Tumultuous Times – Readers Turn to ‘Healing Fiction’

TURN OFF CNN – Nov. 7, 2024 - At Toshikazu Kawaguchi’s book signings, it’s not…

5 hours ago

More Layoffs at Addiction Recovery Care Cuts Nearly Quarter of its Workforce

86ed AGAIN? – NOV. 4, 2024 - Two previous rounds of employee cuts in September…

5 hours ago

Winners Foundation Marks 40-Years Helping Racetrack Workers Overcome Alcoholism & Addiction

BY A NOSE – Nov. 5, 2024 - Thoroughbred owner and recovering alcoholic Gino Roncelli…

5 hours ago

Health Issues And Dr. Pepper Addiction

VIDEO – NO VALUE AT ALL – Nov. 4, 2024 - It all started innocently…

5 hours ago

Medicaid Funding Hasn’t Curbed Overdose Deaths

WHAT WOULD? – Nov. 4, 2024 - Stephan Lindner, Ph.D., is lead author on a…

5 hours ago